Failed Study Turns Allos’ Therapeutics Inc (ALTH) Focus, Drives Shares Up
Allos Therapeutics Inc. (NASDAQ: ALTH), a biopharmaceutical company engaged in the development and commercialization of small molecule drugs for the treatment of cancer, announced today the results from its ENRICH study failed to meet its primary endpoint.ENRICH is the company's pivotal Phase 3 study of Efaproxyn combined with whole brain radiation therapy (WBRT) in women with brain metastases (cancer) originating from breast cancer. The study failed to reach its goal of demonstrating a significant improvement in overall survival in patients receiving the drugs in combination, as compared to those patients only receiving WBRT. Women participating in the study were given…